Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Anne Leselbaum"'
Autor:
Marie Paule Richard, Maria Nachury, Daniel C. Baumgart, Marc Ferrante, Jean-Frederic Colombel, Anne Leselbaum, Jean Charles Grimaud, Damián García-Olmo, Axel Dignass, Julián Panés, Walter Reinisch, Fernando de la Portilla, Silvio Danese, Eran Goldin, Gert Van Assche, Lili Kazemi-Shirazi
Publikováno v:
The Lancet. 388:1281-1290
Summary Background Complex perianal fistulas in Crohn's disease are challenging to treat. Allogeneic, expanded, adipose-derived stem cells (Cx601) are a promising new therapeutic approach. We aimed to assess the safety and efficacy of Cx601 for treat
Autor:
Anne-Marie Kirsten, Anne Leselbaum, Rosa Segarra, Pierluigi Paggiaro, Jutta Beier, Pawel Sliwinski, Jordi Dorca, Marcel Mallet, Claus Vogelmeier, Beatriz Seoane
Publikováno v:
European Respiratory Journal. 48:1030-1039
The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium
Publikováno v:
Clinical Pharmacology in Drug Development. 5:109-117
Inhaled, long-acting bronchodilators represent a cornerstone of maintenance treatment for chronic obstructive pulmonary disease (COPD). Aclidinium bromide/formoterol fumarate 400/12 μg fixed-dose combination (FDC) has recently been licensed for use
Autor:
Anne Leselbaum, Stephen I. Rennard, James F. Donohue, Anthony D'Urzo, Edward Kerwin, Eduard Molins, Alejhandra Lei
Publikováno v:
Respiratory medicine. 125
Introduction Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 μg efficacy and safety was demonstrated in two 6-month Phase III studies (AUGMENT and ACLIFORM) and a 12-month study in patients with moderate to severe chronic obstructive pulmonary
Autor:
Julián Panés, Damián García-Olmo, Gert Van Assche, Jean Frederic Colombel, Walter Reinisch, Daniel C. Baumgart, Axel Dignass, Maria Nachury, Marc Ferrante, Lili Kazemi-Shirazi, Jean C. Grimaud, Fernando de la Portilla, Eran Goldin, Marie Paule Richard, Mary Carmen Diez, Ignacio Tagarro, Anne Leselbaum, Silvio Danese, Jean F. Colombel, Anton Stift, Jörg Tschmelitsch, Karl Mrak, Herbert Tilg, Irmgard Kroberger, André D’Hoore, Danny De Looze, Filip Baert, Paul Pattyn, Philippe Zerbib, Frank Zerbib, Stéphanie Viennot, Jean-Louis Dupas, Pierre-Charles Orsoni, Xavier Hebuterne, Amine Rahili, Matthieu Allez, Yves Panis, Max Reinshagen, Roland Scherer, Andreas Sturm, Wolfgang Kruis, Daniel-Simon Duek, Matti Waterman, Adi Lahat-Zok, Oded Zmora, Hagit Tulchinsky, Yair Edden, Antonino Spinelli, Vito Annese, Imerio Angriman, Gabriele Riegler, Francesco Selvaggi, Bas Oldenburg, Lennard Gilissen, Gust Van Montfort, Mark Lowenberg, Adrianus Willem Bemelman, Raúl Almenara, María Dolores Martín Arranz, Mariano García-Arranz, Javier Pérez Gisbert, Rosana Palasí, Carlos Taxonera Samsó, Jose Manuel Herrera Justiniano, Ricardo Rada, Mª Teresa Butrón, Daniel Carpio López, Antonio López-Sanromán, Joaquín Hinojosa de Val, Amparo Solana, F. Xavier González Argenté, Carlos Pastor, Hector Guadalajara
Publikováno v:
Gastroenterology, 154(5), 1334-1342.e4. W.B. Saunders Ltd
Background & Aims: Therapies for perianal fistulas in patients with Crohn's disease are often ineffective in producing long-term healing. We performed a randomized placebo-controlled trial to determine the long-term efficacy and safety of a single lo
Autor:
Anthony D'Urzo, Ferran Chuecos, James F. Donohue, Dave Singh, Anne Leselbaum, Esther Garcia Gil
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Background: Combining two bronchodilators with different mechanisms of action may provide additional benefits versus monotherapy in patients with COPD. Aim: To assess the effect of twice-daily (BID) aclidinium bromide/formoterol fumarate fixed-dose c
Autor:
Esther Garcia Gil, Beatriz Seoane, Anne-Marie Kirsten, Anne Leselbaum, Jordi Dorca, Pierluigi Paggiaro, Pawel Sliwinski, Claus F. Vogelmeier, Rosa Segarra, Marcel Mallet
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Background: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) twice daily (BID) is licensed in Europe for COPD treatment. Aim: To evaluate the efficacy of aclidinium/formoterol vs salmeterol/fluticasone propionate FDC (SAL/FLU) in p
Autor:
Eduard Molins, Dave Singh, Eric D. Bateman, Anthony D'Urzo, Kenneth R. Chapman, Esther Garcia Gil, Anne Leselbaum
Publikováno v:
Respiratory Research
Background The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients with chr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42bfe43ca14fd977b775863b0fdeb8a0
Autor:
Paul W. Jones, Anne Leselbaum, Dave Singh, V Mergel, E Molins, Paul D. Scanlon, Stephanie Korn
Publikováno v:
Pneumologie. 69
Background Aclidinium/formoterol fixed-dose combination (FDC) is in development for the management of COPD. The ACLIFORM and AUGMENT studies assessed the effects of twice-daily FDC on health status in patients with moderate to severe COPD. Method ACL
Publikováno v:
Pituitary. 2:269-276
Objective: To determine the effects of the new somatostatin analogue, lanreotide, in its prolonged released form (PR), in patients with acromegaly.